Mitochondrial dysfunction and mitophagy in Parkinson's Disease: From mechanism 
to therapy

Malpartida, Ana Belen; Williamson, M.; Narendra, D. P.; Wade-Martins, R.; Ryan, B. J.

doi:10.1016/j.tibs.2020.11.007

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Mitochondrial dysfunction and mitophagy in Parkinson's Disease: From mechanism to therapy

MPS-Authors

There are no MPG-Authors in the publication available

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Malpartida, A. B., Williamson, M., Narendra, D. P., Wade-Martins, R., & Ryan, B. J. (2021). Mitochondrial dysfunction and mitophagy in Parkinson's Disease: From mechanism to therapy. Trends in biochemical sciences, 46(4), 329-343. doi:10.1016/j.tibs.2020.11.007.

Cite as: https://hdl.handle.net/21.11116/0000-000F-2014-6

Abstract

Mitochondrial dysfunction has been associated with neurodegeneration in Parkinson's disease (PD) for over 30 years. Despite this, the role of mitochondrial dysfunction as an initiator, propagator, or bystander remains undetermined. The discovery of the role of the PD familial genes PTEN-induced putative kinase 1 (PINK1) and parkin (PRKN) in mediating mitochondrial degradation (mitophagy) reaffirmed the importance of this process in PD aetiology. Recently, progress has been made in understanding the upstream and downstream regulators of canonical PINK1/parkin-mediated mitophagy, alongside noncanonical PINK1/parkin mitophagy, in response to mitochondrial damage. Progress has also been made in understanding the role of PD-associated genes, such as SNCA, LRRK2, and CHCHD2, in mitochondrial dysfunction and their overlap with sporadic PD (sPD), opening opportunities for therapeutically targeting mitochondria in PD.